Pfizer: Growing Beyond Covid

Summary:

  • Pfizer continues to transition to a strong future with reduced Covid drug sales.
  • The biopharma has a strong lineup of new drugs whether via FDA approval or acquisition.
  • The stock has a large dividend yield of 5.9%.
  • Pfizer continues to trade at only 10x ’25 EPS targets.

Pfizer

no_limit_pictures

The key to 2024 for Pfizer Inc. (NYSE:PFE) is moving the business far beyond the Covid drugs dip in a transition year. The biopharma is back in growth mode, but the stock market still hasn’t caught on to


Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock, you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


If you’d like to learn more about how to best position yourself in under valued stocks mispriced by the market to start August, consider joining Out Fox The Street

The service offers a model portfolio, daily updates, trade alerts and real-time chat. Sign up now for a risk-free 2-week trial. 

Leave a Reply

Your email address will not be published. Required fields are marked *